EMA Authorised: BeneFIX (nonacog alfa) — Pfizer Europe MA EEIG

View source ↗

Summary

The European Medicines Agency authorised BeneFIX (nonacog alfa) for Hemophilia B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BeneFIX (recombinant coagulation factor IX concentrate)

Snippet

Status: Authorised. Therapeutic area: Hemophilia B. MAH: Pfizer Europe MA EEIG. Decision date: 06/03/2025